Welcome to Pharma Tides Learn — the peptide research library
Why we built a dedicated long-form research library for peptide researchers — and what to expect from it.
Pharma Tides has always done two things in one place: supply reference-grade research peptides, and try to explain — honestly — what those peptides actually do. The shop has been the natural home of the first job. The second never quite fit. Product pages can carry a paragraph; they cannot carry a two-thousand-word essay on retatrutide’s incretin pharmacology, or a careful read of last quarter’s BPC-157 systematic review.
So we built somewhere it could live. learn.phrtides.com is the editorial arm of Pharma Tides — long-form, plain-English research notes on every peptide we supply, plus running commentary on the wider field as new literature appears.
What you’ll find here
The site has two halves.
The Peptide Library is the encyclopaedia. Every research peptide we carry gets a dedicated page covering its mechanism, receptor targets, half-life, observed effects in published studies and — crucially — what the literature still does not know. We have started with the peptides our customers ask about most: BPC-157, TB-500, retatrutide, tirzepatide and melanotan-2. The rest will follow.
The Blog is for everything that does not fit in a single encyclopaedia page: clinical trial read-outs, new-paper breakdowns, regulatory shifts at the MHRA and NICE, supply-chain notes for the laboratory and the occasional “what we changed our minds on” post when a piece of literature genuinely shifts the picture.
What you will not find here
A few things we have deliberately kept out:
- Dosing protocols for human use. Everything we discuss is a research compound under the Human Medicines Regulations 2012. Pretending otherwise would be both dishonest and unlawful.
- Marketing prose. If a peptide’s data is thin, we say so. We would rather be a resource researchers trust than one they read once and never come back to.
- Sponsored placements. Pharma Tides funds this site. Nobody else does.
Tone
We are aiming for something between Nature News and a thoughtful biotech newsletter. Mid-trust, evidence-led, no breathless adjectives. Proper British English throughout. If something is speculative you will see the word “speculative” — not a hedged claim dressed up to sound like a fact.
What is next
The library is the priority for the next few weeks. We are working through the catalogue in order of customer demand — expect new peptide guides roughly weekly. On the blog side, we will start with a series of paper breakdowns covering the most-cited peptide studies of the last twelve months, with extra attention on anything currently under MHRA or NICE review.
If there is a peptide you would like to see covered next, or a study you think we should write up, message the team on WhatsApp. We read everything.
— The Pharma Tides research team
Written by Pharma Tides Research. This is editorial content from Pharma Tides Learn— not medical advice. Research compounds discussed are supplied by Pharma Tides for in-vitro laboratory research only.